- Active not recruitingPHASE1, PHASE2
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.
For: Ovarian Cancer · Breast Cancer · Pancreatic CancerUnited States · Australia · Canada - Active not recruitingPHASE1
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
This study is looking at a new combination treatment, DS-1103a and T-DXd, for people with advanced solid tumours. It aims to see how safe and effective this new treatment is.
For: Advanced Solid TumorUnited States · Canada · France - RecruitingPHASE3
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
This study offers continued access to a cancer treatment for patients who are already benefiting from it in previous trials. It aims to check the long-term safety and effectiveness of the medication for people with advanced or metastatic cancer.
For: Advanced Cancer · Metastatic CancerUnited States · Australia · Belgium - RecruitingPHASE2
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
This study looks at a new drug (Trastuzumab Deruxtecan, T-DXd) for advanced HER2-positive breast cancer that has spread. It combines this drug with Pertuzumab and uses phone apps and devices to help manage side effects and detect problems early.
For: Breast Cancer Stage IVFrance · Germany · Spain